久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Companies

AstraZeneca ups R&D localization

By Zheng Yiran | China Daily | Updated: 2018-12-04 11:00
Share
Share - WeChat
A man walks past an AstraZeneca site in Macclesfield, north England. [Photo/Agencies]

Global biopharmaceutical giant AstraZeneca PLC is promoting the research and development of seven medicines in China, as the company endeavors to strengthen its local R&D capabilities to lower costs for patients.

According to the company, it will take advantage of its production and logistics bases in Wuxi and Taizhou in Jiangsu province to mass produce high-quality and low-cost medicines.

"In addition to the Chinese market, we supply over 70 countries around the world, mainly developing countries. We will use our production advantages to raise production and lower costs, so that patients can benefit from more reasonable prices," said Wang Lei, CEO of AstraZeneca China.

At the China International Import Expo, the Cambridge, United Kingdom-headquartered company demonstrated roughly 30 innovative products that it had brought to China since entering the country 25 years ago. A renal anemia medication, which is being developed locally in China, was displayed at the expo. The drug is set to make its global debut in China next year.

According to Wang, AstraZeneca hopes to bring its global experience to China through the CIIE. The company hopes to integrate its experience with China's successful internet of things ecosystem, colliding with more creative sparks, to meet the country's ever-changing and upgrading medical needs and pain points, by bringing new solutions for Chinese patients, he said.

Wang said China has evolved into the company's second-largest market. As the second-largest medical consumption market in the world, China is also the company's fastest-growing market, with 12 percent year-on-year growth in 2017, he said.

Company statistics show sales revenues stood at $22.5 billion in 2017, of which $2.96 billion was from China, 13.2 percent of the total.

That makes AstraZeneca the second-largest multinational pharmaceutical company in China. To date, it has invested more than $750 million into R&D of medicines that improve people's quality of life

Having operated in China for 25 years, the company continuously adjusts its development strategy, and is beginning to place a heavier emphasis on local R&D innovation.

"In the past, we merely brought foreign drugs into China. From now on, we will develop new drugs locally in China, and bring the products not only to Chinese patients, but also patients from other developing countries. China's innovative drug imports and market access are accelerating. This shifts our emphasis onto specific medicines and anti-cancer drugs," Wang said.

For AstraZeneca, R&D localization is an important opportunity for multinational pharmaceutical companies, leading it to promote the R&D process of seven new drugs in China.

The innovative products and development models based in China can also be applied to other markets, says the company.

"The innovative business model in China will not only stay in China. After being applied to various therapeutic fields, the model can be used in other markets. In the future, governments and medical institutions in other countries will rush to embrace Chinese innovation, and that era is coming soon," Wang said.

Yang Wenya, a medical analyst with Beijing-headquartered think tank EO Intelligence, said: "For medical companies, local innovation in developing new medicines takes advantage of the local production advantages to cut costs and raise efficiency, throughout the process of R&D, production and transportation. In this way, both medical companies and patients benefit. This is an inevitable trend of the international division of labor."

She said China's large patient pool offers abundant resources for clinical research and data is easy to access.

"Producing medicine locally saves the cost of transporting medicines. Also, the two major production logistics bases in Wuxi and Taizhou have obvious agglomeration and scale effects, which can guarantee the quality and quantity of drugs," Yang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 色综合在 | 香蕉成人 | 国产一区二区三区不卡在线观看 | 成人毛片国产a | 97se狠狠狠狠狠亚洲综合网 | 九九国产在线 | 日韩在线精品视频 | 最新欧美一级视频 | 亚洲欧美小视频 | 国产一区二区三区四区波多野结衣 | gay毛片 | 国产老鸭窝毛片一区二区 | 521a久久九九久久精品 | 欧美亚洲国产成人精品 | 三级网址在线观看 | 中国老妇色xxxxx | 欧美一级成人一区二区三区 | 国产在线精品一区二区三区 | 一区二区三区免费看 | cao在线视频 | 久久国产精品一区二区三区 | 久草在线最新视频 | 日韩一级片在线播放 | www色午夜| 成人国产精品久久久免费 | 手机在线免费看毛片 | 成人夜色香网站在线观看 | 手机看片神马午夜 | 一级毛片视频免费 | 午夜在线观看视频免费 成人 | 成人亚洲精品一区二区 | 男女性关系视频免费观看软件 | 日韩女人做爰大片 | baoyu121永久免费网站 | 男人天堂1024| 日韩制服诱惑 | 手机看片日韩日韩国产在线看 | 91香焦国产线观看看免费 | 女人把腿劈开让男人桶的网站 | 日本毛片在线 | 在线播放亚洲视频 |